Back to search results

MyCondro™ for Joint Health and Mobility in Knee Osteoarthritis

This study is looking at how well two different doses of MyCondro™ (300mg and 600mg), a non-animal chondroitin sulfate supplement, help with joint health and physical mobility. You might be able to join if you are 45 or older, have a BMI between 18-35, and have had ongoing knee osteoarthritis pain and mobility issues for at least 6 months. The main goal is to see if MyCondro™ improves your overall joint health and mobility, measured by changes in your WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores over 12 weeks. The study is currently unclear on its recruitment status and plans to enroll 240 people.

Study design
This is a decentralized, double-blind study, meaning neither you nor the researchers will know which dose of MyCondro™ you are receiving. It aims to enroll 240 participants.
What's involved
The study involves a screening period, randomization, and a 12-week period of using the product. You will collect data at home using wearable devices.
Compensation
Not stated in the trial record.
Follow-up
The primary effectiveness of MyCondro™ is measured at 12 weeks after starting the product.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07493239

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

Recruiting
NAAges 45+InterventionalSupportive care
Lesaffre International
~240 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:MyCondro 300mgMyCondro 600mg

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
MyCondro's effectiveness
Measured over 12 weeks

Conditions

Joint Health

Explore related trials

Osteoarthritis of knee

NCT07493239

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • People Science

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Noah Craft, MD, PhD · PRINCIPAL_INVESTIGATOR · People Science, Inc.

Who to contact

Victoria Oyedokun, PhD
[email protected]
+4915163496903
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals age 45 years and older.
BMI range between 18-35 kg/m².
Self-reported mobility issues, including mobility impairment and joint discomfort associated with a known diagnosis of Knee Osteoarthritis. This impairment and discomfort must have persisted for at least 6 months prior to randomization and have been actively experienced within the last 3 months.
Willingness to avoid high Chondroitin Sulfate-containing foods (i.e., animal cartilages, bones, or derivatives such as gelatin) for the duration of the study period.
Willingness to refrain from supplements containing Chondroitin Sulfate for the duration of the study period.
Able to read and understand English.
Able to read, understand, and provide informed consent.
Able to use a personal smartphone device and download the Chloe by People Science app.
Able to receive shipments of the product at an address within the United States.
Able to complete study assessments over the course of up to 16 weeks.

Exclusion

Technology Limitation: Do not have a personal smartphone, lack internet access, or are unwilling to download the Chloe app.
Concomitant Therapies

What this trial measures

  • MyCondro's effectiveness12 weeks

    To evaluate the effectiveness of two different doses of MyCondro on mobility, activity, and joint health by measuring the change in total WOMAC scores from baseline to the end of the study within each dose group